Key result
DRAQ7 eliminates doxorubicin auto-fluorescence in cancer cells to enable precise apoptotic differentiation during flow cytometry.
Why the study?
DOX intrinsic fluorescence interferes with accurate detection during flow cytometric cell death assays like Annexin V/PI or Annexin V/7AAD.
DRAQ7 provides a reliable method for flow cytometric analysis of doxorubicin-treated cells by overcoming the drug's intrinsic autofluorescence.
May refine apoptosis assays in doxorubicin research; leaves open clinical translation in cardio-oncology.
Doxorubicin (DOX) is a widely used chemotherapeutic agent that induces apoptosis through DNA intercalation, topoisomerase II inhibition, and oxidative stress. However, its cardiotoxicity is a significant concern. Flow cytometry, particularly with Annexin V/propidium iodide (PI) or Annexin V/7AAD assays, is commonly used to assess DOX-induced cell death. A challenge arises from DOX's intrinsic fluorescence, which interferes with accurate detection. To address this, we successfully used DRAQ7, a far-red dye, in HeLa and other cancer cell lines. As our study demonstrates DRAQ7 eliminates auto-fluorescence interference, this approach offers precise differentiation of apoptotic cells and improving experimental and therapeutic reliability.
No takes yet. Share an insight, caveat, or question.
Çiftçi et al. (2026) studied Doxorubicin-induced cell death. DRAQ7 was evaluated on Differentiation of apoptotic cells without auto-fluorescence interference. The use of DRAQ7, a far-red dye, eliminated doxorubicin auto-fluorescence interference in cancer cell lines, enabling precise differentiation of apoptotic cells during flow cytometry.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: